363 related articles for article (PubMed ID: 16424052)
1. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
2. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
3. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE
J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593
[TBL] [Abstract][Full Text] [Related]
4. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.
Herkel J; Jagemann B; Wiegard C; Lazaro JF; Lueth S; Kanzler S; Blessing M; Schmitt E; Lohse AW
Hepatology; 2003 May; 37(5):1079-85. PubMed ID: 12717388
[TBL] [Abstract][Full Text] [Related]
5. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
6. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
7. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
[TBL] [Abstract][Full Text] [Related]
8. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
Martin BK; Frelinger JG; Ting JP
J Immunol; 1999 Jun; 162(11):6663-70. PubMed ID: 10352284
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
11. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
[TBL] [Abstract][Full Text] [Related]
12. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
13. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.
Dissanayake SK; Thompson JA; Bosch JJ; Clements VK; Chen PW; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2004 Mar; 64(5):1867-74. PubMed ID: 14996751
[TBL] [Abstract][Full Text] [Related]
14. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
[TBL] [Abstract][Full Text] [Related]
15. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
[TBL] [Abstract][Full Text] [Related]
16. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA.
Bradley MB; Fernandez JM; Ungers G; Diaz-Barrientos T; Steimle V; Mach B; O'Reilly R; Lee JS
J Immunol; 1997 Aug; 159(3):1086-95. PubMed ID: 9233601
[TBL] [Abstract][Full Text] [Related]
17. CIITA enhances HIV-1 attachment to CD4+ T cells leading to enhanced infection and cell depletion.
Porter KA; Kelley LN; Nekorchuk MD; Jones JH; Hahn AB; de Noronha CM; Harton JA; Duus KM
J Immunol; 2010 Dec; 185(11):6480-8. PubMed ID: 21041720
[TBL] [Abstract][Full Text] [Related]
18. Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.
Rickard S; Ono SJ
Exp Mol Pathol; 2008 Dec; 85(3):147-54. PubMed ID: 18952077
[TBL] [Abstract][Full Text] [Related]
19. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
Cycon KA; Rimsza LM; Murphy SP
Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
[TBL] [Abstract][Full Text] [Related]
20. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells.
Le E; Zhang H; Blanck G
Anticancer Res; 2005; 25(6B):3889-92. PubMed ID: 16312044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
